PDCD1 and non-small cell lung carcinoma: The phase III clinical trials KEYNOTE‐407, KEYNOTE‐189, and IMpower150 have indicated that a combination of chemotherapy and anti‐PD‐1/PD‐L1 inhibitors improved antitumor efficacy than chemotherapy alone in NSCLC patients.12, 32, 33